Jazz Pharma to buy GW Pharma for $7.2 billion, adding cannabis-based drug to portfolio
(Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment.
